Meeting
2014 ASCO Annual Meeting
Adjuvant taxane therapy for early-stage breast cancer: A real-world comparison of chemotherapy regimens in Ontario.
Authors
Sofia Torres
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Sofia Torres , Maureen E. Trudeau , Andrea Eisen , Craig Earle , Kelvin K. Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1081)
DOI
10.1200/jco.2014.32.15_suppl.1081
Abstract #
1081
Poster Bd #
174
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.
First Author: Danilo Giffoni M. M. Mata
Poster
2015 Breast Cancer Symposium
Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH).
First Author: Rosana Gnanajothy
Poster
2012 Breast Cancer Symposium
Adjuvant chemotherapy for early-stage breast cancer: Choice of regimen and associated hematologic toxicities in a metropolitan Australian hospital.
First Author: Katherine Lovat
Poster
2021 ASCO Annual Meeting
Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.
First Author: Fangchao Zheng